Impact BioMedical, INC. Preferred Stock, Shares Authorized
Impact BioMedical, INC. (IBO) had Preferred Stock, Shares Authorized of 100.00 million shares as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Stockholders' Equity, Number of Shares, Par Value and Other Disclosure › Preferred Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:PreferredStockSharesAuthorized · last filed 2026-08-07
- 2026-06-30: Preferred Stock, Shares Authorized 100.00M shares.
- 2026-03-31: Preferred Stock, Shares Authorized 100.00M shares.
- 2025-12-31: Preferred Stock, Shares Authorized 100.00M shares.
- 2025-09-30: Preferred Stock, Shares Authorized 100.00M shares.
| Period end | Preferred Stock, Shares Authorized |
|---|---|
| 2026-06-30 | 100.00M shares 10-Q · filed 2026-08-07 |
| 2026-03-31 | 100.00M shares 10-Q · filed 2026-05-12 |
| 2025-12-31 | 100.00M shares 10-Q · filed 2026-08-07 |
| 2025-09-30 | 100.00M shares 10-Q · filed 2025-11-07 |
| 2025-06-30 | 100.00M shares 10-Q · filed 2025-08-14 |
| 2025-03-31 | 100.00M shares 10-Q · filed 2025-05-14 |
| 2024-12-31 | 100.00M shares 10-K · filed 2026-03-11 |
| 2024-09-30 | 100.00M shares 10-Q · filed 2024-11-12 |
| 2024-06-30 | 100.00M shares 10-Q · filed 2024-08-13 |
| 2024-03-31 | 100.00M shares 10-Q · filed 2024-05-10 |
| 2023-12-31 | 100.00M shares 10-K · filed 2025-03-28 |
| 2022-12-31 | 100.00M shares 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |